2 unknown. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Unknown 2 |
Follow Anlotinib: new trials by email Literature Review of Anlotinib trials Research Report on Anlotinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody Anlotinib, Penpulimab - Lung Cancer, TKI Resistance | Phase 3 | Unknown | Degan Lu | 52 | 2023-09-01 | 2023-09-21 |
| Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC Anlotinib and TQB2450 solution, TQB2450 solution - Hepatocellular Carcinoma, Thermal Ablation | Phase 3 | Unknown | Chinese PLA General Hospital | 80 | 2021-03-05 | 2021-03-04 |
Carcinoma, Hepatocellular (1) · Lung Neoplasms (1)
Neoplasms (2) · Neoplasms by Site (2) · Adenocarcinoma (1) · Carcinoma (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Liver Diseases (1) · Liver Neoplasms (1) · Lung Diseases (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1)
anlotinib (2) · penpulimab (1)
Chinese PLA General Hospital (1) · Degan Lu (1)
China (1)
PMID 27413711, PMID 28486985, PMID 29438373, PMID 30419091, PMID 33433946, PMID 33791214, PMID 34327136, PMID 35875118